News Seven future blockbuster drugs to look out for in 2019 AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make blockbuster sales by 2023.
News Hengrui to file obesity shot in China after phase 3 win An obesity therapy developed Hengrui Pharma and Kailera is being prepared for its first regulatory submission, in China.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
